Agilent is collaborating with Florida International University’s department of chemistry and biochemistry and its International Forensics Research Institute to further advance the identification and characterization of so-called designer drugs. Designer drugs — novel analogs or derivatives of existing illicit drug compounds– are synthesized to circumvent existing laws and to produce similar effects as illegal recreational drugs.
The partnership is focused on developing and validating new methods for rapid forensic screening and analysis based on advanced chromatography and mass-spectrometry systems such as LC-QQQ-MS/MS, LC-QTOF-MS, GC/MS and GC/MS/MS. These new procedures will expand the capabilities of traditional drug-screening procedures involving immunoassays.
“It is our goal to provide private, academic and government institutions with sophisticated technology and screening methods that will quickly and accurately identify these substances so that laws enacted to restrict their use can be readily enforced,” said Tom Gluodenis, Agilent’s global marketing manager of Forensics and Toxicology.
For more information go to: